Researchers are studying a blood test targeting miR-371a-3p, a microRNA biomarker that may improve how doctors predict testicular cancer recurrence after treatment. Early results from the CLIMATE study show strong potential, but the test is not yet part of standard surveillance guidelines.
Researchers are studying a new type of blood test that could improve how doctors monitor for testicular cancer recurrence after initial treatment.
The test focuses on miR-371a-3p, a microRNA that has shown strong potential as a biomarker for testicular germ cell tumors. Unlike traditional markers such as AFP, hCG, and LDH, miR-371 appears to be more sensitive to active disease. One important limitation: the test does not detect teratoma, a subtype of germ cell tumor, which is a factor clinicians need to account for when interpreting results.
Early results from the CLIMATE study, presented at the 2026 ASCO Genitourinary Cancers Symposium, suggest the test may help identify which patients are more likely to experience recurrence after orchiectomy.
In this study, the test demonstrated a positive predictive value (PPV) of 62% and a negative predictive value (NPV) of 91%.
These findings are promising, particularly for patients with stage I disease, where recurrence risk is a central concern. Recurrence rates vary significantly by subtype, ranging from roughly 9% in seminoma to as high as 38% in non-seminoma patients on surveillance.
It is important to understand where things stand today.
These results are based on early data presented at a scientific conference, not yet a fully published, peer-reviewed study. While miR-371 has consistently shown strong performance across multiple studies, it is not currently part of standard surveillance guidelines.
Current monitoring approaches, including imaging and traditional tumor markers, remain the standard of care. They are effective but have limitations, which is why new tools like miR-371 are being actively studied.
If further validated, this type of blood test could meaningfully improve how recurrence risk is assessed and potentially reduce uncertainty for patients.
For now, it represents one of the most promising developments in testicular cancer surveillance, but not yet a clinical replacement for existing methods.
Beyond the clinical data, it is also worth acknowledging the patient experience. Even years after treatment, many survivors report ongoing fear of recurrence, underscoring the importance of better monitoring tools and clearer signals.
As research continues, the goal is not just earlier detection, but greater confidence in what comes next.
Your gift keeps every guide, chat, and support call free. TCF is a 501(c)(3) nonprofit. Donations are tax-deductible.
